Value, Pricing, and Access in the New Healthcare Landscape

Healthcare is moving towards a new model, wherein digital technology, data analytics, and artificial intelligence are seamlessly integrated with traditional care methods like medications and other therapeutic interventions. Value, pricing, and access methods must therefore adapt to this new paradigm. In a new Ipsos point of view paper, Chris Teale, Senior VP of Ipsos’s European Market Access Team breaks down the challenges the industry faces and possible solutions to them.

This approach, according to Steele, “will need to be re-engineered to address 4 factors.

• Science and Technology: The biggest disruptor to the healthcare landscape of the future.
• Multi-component Disease Management: The linking of patient-level real-world/real-time data – together with biomarker informed precision medicine/personalized healthcare.
• Multi-Stakeholder Value Attribution: A shift in focus from the assessment of a drug or device in isolation to a more holistic assessment of the value of healthcare – disease prevention and disease management.
• Multi-source data integration: Regulatory and health Technology Assessments increasingly embracing data and evidence beyond traditional randomized controlled trials.”

To learn more and download the paper, click here.

(Source: Ipsos, March 28^th, 2022)